CaseVu
Precipio To Distribute HemeScreen® Through Fisher Healthcare Channel
Agreement Enhances Precipio’s Product Reach to US Laboratories NEW HAVEN, CT – (Globe Newswire) – [...]
Jul
Precipio Requests That All Stockholders That Have Not Yet Voted, Proceed To Cast Their Vote
Meeting Adjourned, new meeting set for July 5th at 10am EDT NEW HAVEN, CT – [...]
Jun
Keith Meadors Joins Precipio To Lead Its Products Division
Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations NEW [...]
Jun
Precipio Receives CE-IVD Certification To Market Multiple HemeScreen® Panels In Europe
This Regulatory Approval Opens the Company’s Reach to the European Market NEW HAVEN, CT – [...]
May
Precipio Signs First IV-Cell Customer Agreement
Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential NEW HAVEN, CT – (Globenewswire) [...]
May
Precipio Customer American Oncology Network (AON) Selected To Present HemeScreen® Technology Case Study At Industry Leading Clinical Laboratory Conference
NEW HAVEN, CT – (Apr 26th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited [...]
Apr
Precipio Announces 2021 Fourth Quarter And Year-End Shareholder Update Call
Conference Call to be held on Monday, April 4th, 2022 at 5:00 PM EST NEW [...]
Mar
Precipio Inc. Announces The Resignation Of Its Chief Financial Officer And Appointment Of Interim CFO
NEW HAVEN, CT, (Mar 21st, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that [...]
Mar
Precipio Releases Year-End 2021 Preliminary Unaudited Results And Outlook For 2022
NEW HAVEN, CT, (Feb 24th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced its [...]
Feb
New York State Approves Precipio’s HemeScreen For POL Clinical Use
New York Cancer & Blood POL will commence the use of HemeScreen in its laboratory [...]
Nov